Wei-Li Hsu | Immunology | Women Researcher Award

Prof. Dr. Wei-Li Hsu | Immunology | Women Researcher Award

Professor and Director of Graduate Institute at National Chung Hsing University | Taiwan

Prof. Wei-Li Hsu is a distinguished academic and researcher with extensive expertise in molecular virology and veterinary medicine. Over the years, she has established himself as a leading scholar through his pioneering research, impactful publications, and academic leadership, contributing significantly to both fundamental science and applied biomedical research.

Professional Profile

Scopus

Google Scholar

Educational Background 

She holds a Ph.D. in Molecular Virology from the University of Glasgow, UK, building on a Master’s degree in Veterinary Microbiology and a Doctor of Veterinary Medicine degree from National Chung-Hsing University, Taiwan. This solid academic foundation provided him with interdisciplinary expertise spanning veterinary sciences and advanced virological research.

Professional Experience 

Prof. Hsu has built a long and distinguished career at National Chung-Hsing University (NCHU), Taiwan, where she progressed from Assistant Professor to Associate Professor, Professor, and later Distinguished Professor. She has also served in leadership roles such as Director of the Graduate Institute of Microbiology & Public Health and Associate Dean of the College of Veterinary Medicine. His international career includes postdoctoral research at the University of Alberta, Canada, and the University of Cambridge, UK, along with visiting professorships at the Tokyo University of Agriculture and Technology, Japan, and a visiting scholar appointment at the Icahn School of Medicine at Mount Sinai, USA.

Research Interests 

Her research centers on molecular virology, with a particular focus on influenza viruses, herpesviruses, and the use of viral vectors for therapeutic purposes. His work spans viral pathogenesis, immunogenicity, vaccine development, and the application of attenuated viruses as safe vectors for cancer treatment. She has also contributed to advancing virus-like particle production and the development of novel antiviral strategies.

Awards and Honors 

Prof. Hsu has been repeatedly recognized for his academic excellence. She has held the title of Distinguished Professor at National Chung-Hsing University across multiple terms and received the Outstanding Young Researcher Award from the same institution on several occasions. During his doctoral studies in the UK, she was awarded the prestigious Overseas Research Student Award and postgraduate scholarships from the University of Glasgow.

Research Skills 

She possesses advanced expertise in molecular virology, including viral vector engineering, immunological evaluation of viral antigens, vaccine development, and translational applications of virological research. In addition, his leadership and mentorship skills have enabled him to guide research teams, foster academic collaborations, and contribute to the development of future scientists.

Publication Top Notes

  • Inhibition of enveloped viruses infectivity by curcumin

  • Cited by: 203

  • Year: 2013

  • The first discovery of severe fever with thrombocytopenia syndrome virus in Taiwan

  • Cited by: 146

  • Year: 2020

  • Bovine lactoferrin inhibits Japanese encephalitis virus by binding to heparan sulfate and receptor for low density lipoprotein

  • Cited by: 113

  • Year: 2008

  • Urine neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute canine kidney injury

  • Cited by: 107

  • Year: 2012

  • Bovine lactoferrin inhibits dengue virus infectivity by interacting with heparan sulfate, low-density lipoprotein receptor, and DC-SIGN

  • Cited by: 97

  • Year: 2017

Conclusion 

Prof. Wei-Li Hsu’s career demonstrates a profound commitment to advancing knowledge in molecular virology and veterinary medicine. Through his outstanding research achievements, international collaborations, and leadership in higher education, she has made a lasting impact on science and global health. His work continues to bridge basic research and clinical applications, positioning him as a prominent figure in the field.

 

Amr Radwan | Immunology | Best Researcher Award

Dr. Amr Radwan | Immunology | Best Researcher Award

Executive Medical Director at Regeneron, United Kingdom

Dr. Amr AH Radwan is a distinguished medical affairs leader with over two decades of global experience spanning clinical medicine, pharmaceutical medicine, immunology, gastroenterology, and strategic leadership in drug development and market access. Currently serving as Executive Medical Director at Regeneron Pharmaceuticals Inc., he brings deep scientific expertise and cross-functional insight to global medical affairs, particularly in immunological disorders and biologics. His work bridges the interface of clinical innovation, medical strategy, regulatory frameworks, and international healthcare markets.

Publication Profile 

Orcid

Educational Background 🎓

  • University of Cambridge

    • MB BChir (Bachelor of Medicine and Surgery), 1998

    • BA in Pathology (Honours), 1996

    • MA (Cantab), 1999

  • Royal College of Surgeons (Edinburgh)

    • AFRCS Part 1 (MCQ I & II), 2001

  • The Berne Institute, Kegworth

    • Foundation Training in Transactional Analysis Counselling & Psychotherapy, 2003

  • University of Cardiff

    • Diploma in Pharmaceutical Medicine, 2010

  • Royal College of Physicians

    • Membership of Faculty of Pharmaceutical Medicine, 2011

    • Specialist Training in Pharmaceutical Medicine, 2011

    • Fellowship, 2016

Professional Experience 💼

🏢 Regeneron Pharmaceuticals Inc. (2018–Present)

  • Executive Medical Director, Global Medical Affairs (2022–Present)

  • Senior Director, Global Medical Affairs (2019–2021)

  • Senior Director, Medical Affairs EU (2018–2019)

    • Key leadership in global immunology franchise across dermatology, respiratory, and GI indications (e.g., Dupilumab, Itepekimab).

    • Led GI franchise (EoE, EoG, eUC) strategy and ex-US medical organization restructuring.

    • Partnered with commercial, legal, and R&D teams for European, Canadian, and Japanese market expansions.

🏢 Aimmune Therapeutics Ltd. (2016–2018)

  • Vice President, Medical Affairs & Market Access

    • EU and global leadership for peanut allergy therapy; directed Drug Safety & PV, Market Access, and clinical trial governance.

🏢 Norgine Pharmaceuticals UK Ltd. (2014–2016)

  • Medical Director – EU

    • Led EU medical affairs, market access, PV, and NICE submission strategies; managed 8 country-level medical teams; oversaw clinical trials and licensing responses.

Research Interests 🔬

  • Pharmaceutical Medicine & Clinical Drug Development

  • Immunology, Dermatology, and Gastroenterology (e.g., EoE, PN, CRSwNP)

  • Allergic Disorders and Biologics (e.g., anti-IL33, anti-Fel D1)

  • Regulatory Compliance, Pharmacovigilance & Risk Management

  • Clinical Strategy and Market Access Studies

Awards and Honors🏆✨

  • Queens’ College Exhibition Prize (1994–1996)
    Awarded for First Class academic performance in Preclinical Sciences.

  • Fawcett Memorial Prize (1998)
    Recognized for Outstanding Communication Skills.

  • Fellowship of the Faculty of Pharmaceutical Medicine (2016)
    Awarded by Royal College of Physicians for significant contributions to Pharmaceutical Medicine.

Additional Credentials & Interests

  • Languages & Communication: Fluent in Arabic, English, and French.

  • Advanced Certifications:

    • IAM-trained motorcyclist (Institute of Advanced Motorists)

    • PADI Advanced & BSAC Sports Scuba Diving certifications

  • Hobbies:

    • Partner dancing (Argentine Tango, Blues, Modern Jive)

    • Literature, philosophy, and motorcycling

Conclusion🌟

Dr. Amr AH Radwan is a highly accomplished physician-leader whose contributions have shaped global medical affairs practices, especially in immunology and allergy-based therapeutics. His unique blend of clinical training, regulatory expertise, and cross-continental leadership makes him a significant figure in modern pharmaceutical medicine and translational healthcare strategy. He is well-suited for high-level recognition, awards, and continued leadership in both academic and industry circles.

Publications 📚

  1. 📄 A Real-World Study of Cumulative Steroid Burden Among Patients with Eosinophilic Esophagitis in the United States
    📰 Clinical Gastroenterology and Hepatology (Mar 2025)
    🔗 DOI: 10.1016/j.cgh.2025.01.010


  1. 📄 Baseline Disease Characteristics by Surgery History Among Patients with CRSwNP: AROMA Registry
    📰 American Journal of Otolaryngology (Mar 2025)
    🔗 DOI: 10.1016/j.amjoto.2024.104596


  1. 📄 Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: VOYAGE (Post Hoc)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Mar 2025)
    🔗 DOI: 10.1016/j.jaip.2024.11.014


  1. 📄 Burden of Eosinophilic Esophagitis in Adults and Adolescents: Real-World Analysis
    📰 Diseases of the Esophagus (Mar 3, 2025)
    🔗 DOI: 10.1093/dote/doaf024


  1. 📄 Dupilumab Efficacy in EoE Irrespective of Prior Swallowed Corticosteroids: LIBERTY EoE TREET Trial
    📰 Expert Review of Gastroenterology & Hepatology (Feb 2025)
    🔗 DOI: 10.1080/17474124.2025.2461516


  1. 📄 Current Smoker: A Clinical COPD Phenotype Affecting Disease Progression and Therapy Response
    📰 American Journal of Respiratory and Critical Care Medicine (Feb 12, 2025)
    🔗 DOI: 10.1164/rccm.202407-1379ci


  1. 📄 Dupilumab Induces Long-Term On-Treatment Clinical Remission in Type 2 Asthma
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Jan 2025)
    🔗 DOI: 10.1016/j.jaip.2024.10.009


  1. 📄 Disease Burden and Symptoms Impacting Quality of Life in Pediatric EoE Patients
    📰 Gastro Hep Advances (2024)
    🔗 DOI: 10.1016/j.gastha.2024.08.009


  1. 📄 Real-World Characteristics of Severe Asthma Patients Before Dupilumab: ProVENT Study
    📰 Respiration (2024)
    🔗 DOI: 10.1159/000535390


  1. 📄 Dupilumab Efficacy in Children With Type 2 Asthma on High-/Medium-Dose ICS (VOYAGE)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Dec 2024)
    🔗 DOI: 10.1016/j.jaip.2024.08.038